Haptoglobin for the treatment of sickle cell disease

Bioscience Hypotheses

Volumn 1, Issue 1, 2008, Pages 59-63

  Podmore, Adrian H B ^a  

^a BIO PRODUCTS LABORATORY   (United Kingdom)

Author keywords

Haemolysis; Haptoglobin; Sickle; Vaso occlusive crisis; Vasoconstriction

Indexed keywords

DIMER; HAPTOGLOBIN; HEMOGLOBIN; LACTATE DEHYDROGENASE; NITRIC OXIDE SYNTHASE;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD VESSEL OCCLUSION; DISEASE SEVERITY; DRUG EFFICACY; FRACTIONATION; HEMOGLOBIN DETERMINATION; HEMOLYSIS; HUMAN; NONHUMAN; PAIN ASSESSMENT; PHENOTYPE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SICKLE CELL ANEMIA; VASOCONSTRICTION; VASODILATATION;

EID: 48349091093     PISSN: 17562392     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bihy.2008.01.011     Document Type: Article

References (36)

1. Yoshioka T., Sugimoto T., Ukai T., and Oshiro T. Haptoglobin therapy for possible prevention of renal failure following thermal injury: a clinical study. J Trauma 25 (1985) 281-287
2. Langlois M.R., and Delanghe J.R. Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem 42 (1996) 1589-1600
3. Funakoshi S, Omura T, Ohshiro T. Haptoglobin in aqueous solution and process for preparing the same. US Patent 1997;4061735.
4. Bamm V.V., Tsemakhovich V.A., Shaklai M., and Shaklai N. Haptoglobin phenotypes differ in their ability to inhibit heme transfer from hemoglobin to LDL. Biochemistry 43 (2004) 3899-3906
5. Dalton J, Kumpalume P, Podmore A. Method for the isolation of haptoglobin. Patent 2006;WO2009043062.
6. Jison M.L., Munson P.J., Barb J.J., Suffredini A.F., Talwar S., Logun C., et al. Blood mononuclear cell gene expression profiles characterize oxidant, haemolytic and inflammatory stress of sickle cell disease. Blood 104 (2004) 270-280
7. Philippidis P., Mason J.C., Evans B.J., Nadra I., Taylor K.M., Haskard D.O., et al. Hemoglobin scavenger receptor CD163 mediates interleukin-10 release and heme oxygenase-1 synthesis: anti-inflammatory monocyte-macrophage responses in vitro, in resolving skin blisters in vivo, and after cardiopulmonary bypass surgery. Circ Res 94 (2004) 119-126
8. Schaer D.J., Schaer C.A., Buehler P.W., Boykins R.A., Schoedon G., Alayash A.I., et al. CD163 is the macrophage scavenger receptor for native and chemically modified haemoglobins in the absence of haptoglobin. Blood 107 (2006) 373-380
9. Dobryszycka W. Biological functions of haptoglobin - new pieces to an old puzzle. Eur J Clin Chem Clin Biochem 35 (1997) 647-654
10. Kato G.J., McGowan V., Machado R.F., Little J.A., Taylor 6th J., Morris C.R., et al. Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood 107 (2006) 2279-2285
11. Muller-Eberhard U., Javid J., Liem H.H., Hanstein A., and Hanna M. Plasma concentrations of hemopexin, haptoglobin and heme in patients with various hemolytic diseases. Blood 32 (1968) 811-815
12. Dejam A., Hunter C.J., Pelletier M.M., Hsu L.L., Machado R.F., Shiva S., et al. Erythrocytes are the major intravascular storage sites of nitrite in human blood. Blood 106 (2005) 734-739
13. Mak V., and Davies S.C. The pulmonary physician in critical care* Illustrative case 6: Acute chest syndrome of sickle cell anaemia. Thorax 58 (2003) 726-728
14. Buchanan G.R., DeBaun M.R., Quinn C.T., and Steinberg M.H. Sickle cell disease. Hematology Am Soc Hematol Educ Program (2004) 35-47
15. Gladwin M.T., and Kato G.J. Cardiopulmonary complications of sickle cell disease: role of nitric oxide and hemolytic anemia. Hematology Am Soc Hematol Educ Program (2005) 51-57
16. Nath N.A., Grande J.P., Croatt A.J., Frank E., Caplice N.M., Hebbel R.P., et al. Transgenic sickle mice are markedly sensitive to renal ischemia-reperfusion injury. Am J Pathol 166 (2005) 963-972
17. Tolosano E., Hirsch E., Patrucco E., Camaschella C., Navone R., Silengo L., et al. Defective recovery and severe renal damage after acute hemolysis in hemopexin deficient mice. Blood 94 (1999) 3906-3914
18. Lim S.K., Kim H., Lim S.K., bin Ali A., Lim Y.K., Wang Y., et al. Increased susceptibility in Hp knockout mice during acute hemolysis. Blood 92 (1998) 1870-1877
19. Tolosano E., Fagoonee S., Hirsch E., Berger F.G., Baumann H., Silengo L., et al. Enhanced splenomegaly and severe liver inflammation in haptoglobin/hemopexin double-null mice after acute hemolysis. Blood 100 (2002) 4201-4208
20. Belcher J.D., Mahaseth H., Welch T.E., Otterbein L.E., Hebbel R.P., and Vercellotti G.M. Heme oxygenase-1 is a modulator of inflammation and vaso-occlusion in transgenic sickle mice. J Clin Investig 116 (2006) 808-816
21. Melamed-Frank M., Lache O., Enav B.I., Szafranek T., Levy N.S., Ricklis R.M., et al. Structure-function analysis of the antioxidant properties of haptoglobin. Blood 98 (2001) 3693-3698
22. Nielsen M.J., Petersen S.V., Jacobsen C., Thirup S., Enghild J.J., Graversen J.H., et al. A unique loop extension in the serine protease domain of haptoglobin is essential for CD163 recognition of the haptoglobin-hemoglobin complex. J Biol Chem 282 (2007) 1072-1079
23. Greer J. Model for haptoglobin heavy chain based upon structural homology. Proc Natl Acad Sci U S A 77 (1980) 3393-3397
24. Ettrich R., Brandt W., Kopecky V., Baumruk V., Hofbauerová K., and Pavlícek Z. Study of chaperone-like activity of human haptoglobin: conformational changes under heat shock conditions and localization of interaction sites. Biol Chem 383 (2002) 1667-1676
25. Urushibara N., Kumazaki T., and Ishii S. Haemoglobin-binding site on human haptoglobin. Identification of lysyl residues participating in the binding. J Biol Chem 267 (1992) 13413-13417
26. Maniecki M.B., Moller H.J., Moestrup S.K., and Moller B.K. CD163 positive subsets of blood dendritic cells: the scavenging macrophage receptors CD163 and CD91 are coexpressed on human dendritic cells and monocytes. Immunobiology 211 (2006) 407-417
27. Crawford J.H., Isbell T.S., Huang Z., Shiva S., Chacko B.K., Schechter A.N., et al. Hypoxia, red blood cells, and nitrite regulate NO-dependent hypoxic vasodilation. Blood 107 (2006) 566-574
28. Lim S.K. Consequences of haemolysis without haptoglobin. Redox Rep 6 (2001) 375-378
29. Fagoonee S., Gburek J., Hirsch E., Marro S., Moestrup S.K., Laurberg J.M., et al. Plasma protein haptoglobin modulates renal iron loading. Am J Pathol 166 (2005) 973-983
30. Blum S., Asaf R., Guetta J., Miller-Lotan R., Asleh R., Kremer R., et al. Haptoglobin genotype determines myocardial infarct size in diabetic mice. J Am Coll Cardiol 49 (2007) 82-87
31. Levy A.P., and Moreno P.R. Intraplaque hemorrhage. Curr Mol Med 6 (2006) 479-488
32. Weiner D.L., Hibberd P.L., Betit P., Cooper A.B., Botelho C.A., and Brugnara C. Preliminary assessment of inhaled nitric oxide for acute vaso-occlusive crisis in pediatric patients with sickle-cell disease. JAMA 289 (2003) 1136-1142
33. Minneci P.C., Deans K.J., Zhi H., Yuen P.S., Star R.A., Banks S.M., et al. Hemolysis-associated endothelial dysfunction mediated by accelerated NO inactivation by decompartmentalized oxyhemoglobin. J Clin Investig 115 (2005) 3409-3417
34. Wang X., Tanus-Santos J.E., Reiter C.D., Dejam A., Shiva S., Smith R.D., et al. Biological activity of nitric oxide in the plasmatic compartment. Proc Natl Acad Sci U S A 101 (2004) 11477-11482
35. Gladwin M.T., Schechter A.N., Ognibene F.P., Coles W.A., Reiter C.D., Schenke W.H., et al. Divergent nitric oxide bioavailability in men and women with sickle cell disease. Circulation 107 (2003) 271-278
36. Podmore A, Dalton J. Uses of haptoglobin. Application 60/924090.